3.255USD+0.15%Mkt Cap: 315.84M USDP/E: —Last update: 2026-05-26
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously ad…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap315.84M USD
Enterprise Value202.46M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.41M USD
Revenue/Share—
Last Price3.255 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.28
PEG—
EV/EBITDA-2.36
EV/Revenue—
P/S—
P/B2.71
EPS (TTM)-0.81
EPS (Forward)-0.63
52W Range
1.07021% of range11.46
52W High11.46 USD
52W Low1.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.90%
ROA-42.40%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.08M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-13.84%
Net Debt-119.16M USD
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.01
Current Ratio15.84
Quick Ratio15.61
Book Value/Sh1.234 USD
Cash/Share1.249 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 13, 2020
Splits
Last Split1:50
Split DateOct 13, 2020
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)5.875 USD
Target Range4.000 USD – 10.00 USD
# Analysts8
Ownership
Shares Out.96.29M
Float66.03M
Insiders10.18%
Institutions90.26%
Short Interest
Short Ratio9.1d
Short % Float21.66%
Short % Out.14.34%
Shares Short13.73M
Short (prev mo.)13.35M
Technical
SMA 503.150 (+3.3%)
SMA 2005.463 (-40.4%)
Beta0.67
S&P 52W Chg28.31%
Avg Vol (30d)1.27M
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—